Cell-active dual specificity phosphatase inhibitors identified by high-content screening

Chemistry and Biology

Volumn 10, Issue 8, 2003, Pages 733-742

  Vogt, Andreas ^a   Cooley, Kathleen A ^a   Brisson, Marni ^a   Tarpley, Michael G ^a   Wipf, Peter ^b   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0041913991     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(03)00170-4     Document Type: Article

References (31)

1. Keyse S.M. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12:2000;186-192.
2. Vogt A., Takahito A., Ducruet A.P., Chesebrough J., Nemoto K., Carr B.I., Lazo J.S. Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. J. Biol. Chem. 276:2001;20544-20550.
3. Xia K., Lee R.S., Narsimhan R.P., Mukhopadhyay N.K., Neel B.G., Roberts T.M. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol. Cell. Biol. 19:1999;4819-4824.
4. Pumiglia K.M., Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA. 94:1997;448-452.
5. Nishikawa Y., Wang Z., Kerns J., Wilcox C.S., Carr B.I. Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition. J. Biol. Chem. 274:1999;34803-34810.
6. Lyon M.A., Ducruet A.P., Wipf P., Lazo J.S. Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discov. 1:2002;961-976.
7. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., Beach D. CDC25 phosphatases as potential human oncogenes. Science. 269:1995;1575-1577.
8. Magi-Galluzzi C., Mishra R., Fiorentino M., Montironi R., Yao H., Capodieci P., Wishnow K., Kaplan I., Stork P.J., Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 76:1997;37-51.
9. Wang H., Cheng Z., Malbon C.C. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191:2003;229-237.
10. Denkert C., Schmitt W.D., Berger S., Reles A., Pest S., Siegert A., Lichtenegger W., Dietel M., Hauptmann S. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J. Cancer. 102:2002;507-513.
11. Lazo J.S., Aslan D.C., Southwick E.C., Cooley K.A., Ducruet A.P., Joo B., Vogt A., Wipf P. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem. 44:2001;4042-4049.
12. Lazo J.S., Nemoto K., Pestell K.E., Cooley K., Southwick E.C., Mitchell D.A., Furey W., Gussio R., Zaharevitz D.W., Joo B.et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. 61:2002;720-728.
13. Taing M., Keng Y.F., Shen K., Wu L., Lawrence D.S., Zhang Z.Y. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry. 38:1999;3793-3803.
14. Geran R.I., Greenberg N.H., Macdonald M.M., Schumacher A.M., Abott B.J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 3:1972;1-95.
15. Balis F.M. Evolution of anticancer drug discovery and the role of cell-based screening. J. Natl. Cancer Inst. 94:2002;78-79.
16. Dunstan H.M., Ludlow C., Goehle S., Cronk M., Szankasi P., Evans D.R., Simon J.A., Lamb J.R. Cell-based assays for identification of novel double-strand break-inducing agents. J. Natl. Cancer Inst. 94:2002;88-94.
17. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 286:1999;971-974.
18. Rosania G.R., Chang Y.T., Perez O., Sutherlin D., Dong H., Lockhart D.J., Schultz P.G. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat. Biotechnol. 18:2000;304-308.
19. Giuliano K.A., DeBiasio R.L., Dunlay T., Gough A., Volosky J.M., Zock J., Pavlakis G.N., Taylor D.L. High-content screening. a new aproach to easing key bottlenecks in the drug discovery process J. Biomol. Screen. 2:1997;249-259.
20. Taylor D.L., Woo E.S., Giuliano K.A. Real-time molecular and cellular analysis. the new frontier of drug discovery Curr. Opin. Biotechnol. 12:2001;75-81.
21. Ding G.J., Fischer P.A., Boltz R.C., Schmidt J.A., Colaianne J.J., Gough A., Rubin R.A., Miller D.K. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J. Biol. Chem. 273:1998;28897-28905.
22. Todd J.L., Tanner K.G., Denu J.M. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J. Biol. Chem. 274:1999;13271-13280.
23. Tonks N.K., Neel B.G. From form to function. signaling by protein tyrosine phosphatases Cell. 87:1996;365-368.
24. Denu J.M., Zhou G., Wu L., Zhao R., Yuvaniyama J., Saper M.A., Dixon J.E. The purification and characterization of a human dual-specific protein tyrosine phosphatase. J. Biol. Chem. 270:1995;3796-3803.
25. Stewart A.E., Dowd S., Keyse S.M., McDonald N.Q. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat. Struct. Biol. 6:1999;174-181.
26. Brunet A., Roux D., Lenormand P., Dowd S., Keyse S., Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18:1999;664-674.
27. Nishikawa Y., Carr B.I., Wang M., Kar S., Finn F., Dowd P., Zheng Z.B., Kerns J., Naganathan S. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem. 270:1995;28304-28310.
28. Groom L.A., Sneddon A.A., Alessi D.R., Dowd S., Keyse S.M. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 15:1996;3621-3632.
29. Dowd S., Sneddon A.A., Keyse S.M. Isolation of the human genes encoding the pyst1 and Pyst2 phosphatases. characterisation of Pyst2 as a cytosolic dual-specificity MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases J. Cell Sci. 111:1998;3389-3399.
30. Pu L., Amoscato A.A., Bier M.E., Lazo J.S. Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione. J. Biol. Chem. 277:2002;46877-46885.
31. Rice R.L., Rusnak J.M., Yokokawa F., Yokokawa S., Messner D.J., Boynton A.L., Wipf P., Lazo J.S. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry. 36:1997;15965-15974.